NuVeta is developing the first purpose-built carbon nanotube (CNT) x-ray system for clinical minibeam radiotherapy (MBRT)—an emerging spatially fractionated radiotherapy approach designed to dramatically improve tumor control while minimizing damage to surrounding healthy tissue.
MBRT has shown remarkable normal tissue sparing, effective local tumor control, and promising immunomodulatory effects in both extensive preclinical research and pioneering clinical treatments at Mayo Clinic in Rochester. Early clinical experience suggests MBRT may also enhance the effectiveness of systemic therapies, including immunotherapy, offering new possibilities for treating advanced and therapy-resistant cancers.
NuVeta’s mission is to translate this promising therapy into a modern clinical treatment platform designed specifically for minibeam radiotherapy.
Radiotherapy for shallow tumors, including breast and head-and-neck cancers, remains limited by toxicity to nearby healthy tissues.
As systemic cancer therapies improve and patients live longer, the need for safe and effective reirradiation strategiescontinues to grow. New radiotherapy approaches are urgently needed to control tumors while dramatically reducing normal tissue toxicity and enabling more effective combination with systemic therapies.
Minibeam radiotherapy delivers radiation in alternating high-dose “peaks” and low-dose “valleys” across the treatment field, producing a fundamentally different biological response compared with conventional uniform irradiation.
Clinical experience at Mayo Clinic, treating patients with multiply recurrent, treatment-resistant tumors located at shallow depths, has shown highly encouraging results, including:
Preclinical studies further suggest MBRT may enhance drug delivery and improve the effectiveness of systemic therapies, including immunotherapy, by favorably modulating the tumor microenvironment.
These results indicate that MBRT may offer a transformative treatment option for patients with limited therapeutic alternatives.
Current clinical MBRT treatments rely on traditional kV x-ray systems that were not designed for minibeam therapy. These systems lack key capabilities such as:
These limitations restrict treatment efficiency, precision, and broader clinical adoption.
NuVeta is developing a next-generation clinical MBRT platform powered by carbon nanotube field-emission x-ray technology. This purpose-built system is designed to enable:
NuVeta is working closely with Mayo Clinic, the pioneer of clinical kV MBRT, to guide system design and validate early prototype systems.
By integrating advanced nanotechnology with clinical insight, NuVeta aims to bring modern minibeam radiotherapy systems into cancer centers worldwide, enabling improved tumor control while preserving healthy tissue and enhancing combination cancer therapies.